Media

페이지 정보

본문

“Reduction in Biomarker Accumulation”... Study Published in SCIE-Level Journal International Journal of Molecular Sciences (IJMS)

GemVax & KAEL Co., Ltd. (082270, hereafter GemVax) announced on the 5th that a study confirming the preventive effects of GV1001 on periodontitis, periodontitis-related atherosclerosis, and Alzheimer’s disease was published in the International Journal of Molecular Sciences (IJMS/IF 5.6).

According to Gemvax, the paper titled ‘hTERT Peptide Fragment GV1001 Prevents the Development of Porphyromonas gingivalis-Induced Periodontal Disease and Systemic Disorders in ApoE-Deficient Mice’ was published in IJMS on the 1st. This study builds on prior research, "Inhibition of the Severity of Periodontitis and Periodontitis-associated Vascular Lipid Deposition by GV1001 in Animal Models," which was published in August of last year. The lead author is Professor Emeritus No-hee Park of UCLA’s Dental School, along with eight other researchers.

Periodontitis affects approximately 10 to 15% of the global adult population and has been identified as a risk factor for diseases such as diabetes, atherosclerosis, and dementia, in addition to tooth loss.

The main outcomes of this research highlight GV1001's therapeutic and preventive potential in treating periodontitis, periodontitis-induced atherosclerosis, and Alzheimer’s disease.

The study indicated that administering GV1001 to mice with periodontitis induced by Porphyromonas gingivalis (Pg) and lacking apolipoprotein E (ApoE) helped suppress both periodontal disease and vascular inflammation. Notably, it was observed that GV1001 reduced the buildup of Alzheimer's disease-related biomarkers.

The researchers emphasized, “GV1001 demonstrated a preventive effect against atherosclerosis by reducing vascular inflammation, lowering total cholesterol and low-density lipoprotein (LDL) levels, and reducing the accumulation of amyloid-beta and tau, key biomarkers of Alzheimer’s disease.” They concluded, “This suggests that GV1001 has therapeutic and preventive effects on Alzheimer’s disease in patients with periodontitis.”

A GemVax representative commented, “Given the established relationship between periodontitis and Alzheimer’s disease, the study’s confirmation that GV1001 reduces amyloid-beta and tau accumulation in a periodontitis-induced animal model is a highly positive signal for developing GV1001 as an Alzheimer’s treatment. We will continue to conduct further studies to demonstrate GV1001's therapeutic and preventive potential.”

In addition to these findings, Gemvax is actively engaged in preclinical and clinical trials to validate the diverse effects of GV1001, such as anti-aging, anti-oxidation, and anti-inflammation. The company is efficiently advancing preclinical trials for multiple indications associated with the new drug, alongside a global phase 2 clinical trial aimed at developing a treatment for Alzheimer's disease in the US and Europe, and a domestic phase 2 clinical trial for progressive supranuclear palsy.

※ URL of the paper: https://www.mdpi.com/1422 - 0067/25/11/6126

댓글목록

등록된 댓글이 없습니다.